[1]王序,许红旗,梁洪磊.胶质母细胞瘤的PLK2表达及临床意义[J].中国临床神经外科杂志,2024,29(05):289-294.[doi:10.13798/j.issn.1009-153X.2024.05.011]
　WANG Xu,XU Hong-qi,LIANG Hong-lei.Expression of Polo-like kinase 2 (PLK2) in glioblastoma tissues and its clinical significance[J].,2024,29(05):289-294.[doi:10.13798/j.issn.1009-153X.2024.05.011]
点击复制

胶质母细胞瘤的PLK2表达及临床意义()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
29
期数:
2024年05期
页码:
289-294
栏目:
论著
出版日期:
2024-05-30

文章信息/Info

Title:
Expression of Polo-like kinase 2 (PLK2) in glioblastoma tissues and its clinical significance
文章编号:
1009-153X（2024）05-0289-06
作者:
王序; 许红旗; 梁洪磊
455000河南，安阳市人民医院神经外科（王序、许红旗、梁洪磊）
Author(s):
WANG Xu;  XU Hong-qi;  LIANG Hong-lei
Department of Neurosurgery, Anyang People's Hospital, Anyang 455000, China
关键词:
胶质母细胞瘤; Polo样激酶2（PLK2）; 启动子甲基化; 基因表达; 预后
Keywords:
Glioblastoma multiforme;  Polo-like kinase 2;  Promoter methylation;  Gene expression;  Prognosis
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2024.05.011
文献标志码:
A
摘要:
目的 探讨Polo样激酶2（PLK2）在胶质母细胞瘤（GBM）中表达及临床意义。方法 计算机检索TCGA数据库，获得163个GBM组织、207个正常脑组织的PLK2表达临床资料，分析PLK2的表达情况；检索UALCAN数据库分析PLK1启动子甲基化水平。收集2019年5月至2022年6月手术切除的GBM组织50例及颅脑损伤减压术切除的非肿瘤脑组织20例为对照，RT-PCR分析GBM组织PLK2 mRNA表达，MSP法分析PLK2启动子甲基化状态；同时分析GBM组织PLK1 mRNA表达水平与病人总生存期（OS）的关系。结果 TCGA数据库分析显示，GBM组织PLK2表达水平显著低于正常脑组织（P<0.05），PLK2高表达组GBM病人中位OS显著低于低表达组（P<0.05）。UALCAN数据库分析显示，与正常脑组织相比，GBM组织PLK2启动子甲基化水平较高（P<0.001）。50例GBM组织标本PLK2 mRNA表达量明显低于对照组（P<0.001）。根据GBM组织PLK2 mRNA表达中位值分为高表达组和低表达组，50例GBM中，高表达20例，低表达30例。多因素Cox回归分析显示，PLK2 mRNA高表达是GBM病人生存预后不良的独立影响因素（P<0.05）。Kaplan-Meier曲线显示，PLK2 mRNA低表达GBM病人中位OS更长（15.5个月 vs. 10.0个月；P<0.001）。PLK2高甲基化GBM组织PLK2 mRNA表达水平更低（P<0.001）。结论 GBM组织PLK2呈低表达，可能受其DNA启动子甲基化水平的调节。GBM组织PLK2低表达水平较低的病人可能是GBM的独立预后因素。
Abstract:
Objective To explore the expression of Polo-like kinase 2 (PLK2) in glioblastoma (GBM) tissues and its clinical significance. Methods The TCGA database was retrieved to obtain the clinical data regarding the expression of PLK2 in 163 GBM tissues and 207 normal brain tissues, and subsequently, the expression of PLK2 was analyzed. The UALCAN database was consulted to analyze the methylation level of the PLK1 promoter. The mRNA level of PLK2 was detected by RT-PCR in the GBM tissues obtained from 50 GBM patients who underwent surgery from May 2019 to June 2022 and in the non-tumor brain tissues resected during decompression in 20 patients with traumatic brain injury; the methylation status of the PLK2 promoter was analyzed by the MSP method; concurrently, the relationship between the expression level of PLK1 mRNA in GBM tissues and the overall survival (OS) of patients was analyzed. Results The TCGA database analysis indicated that the expression level of PLK2 in GBM tissues was significantly lower than that in normal cerebral tissues (P<0.05), and the median OS of GBM patients in the high-expression group of PLK2 was significantly lower than that in the low-expression group (P<0.05). The UALCAN database analysis disclosed that the methylation level of the PLK2 promoter in GBM tissues was elevated compared to that in normal cerebral tissues (P<0.001). The expression level of PLK2 mRNA in 50 GBM tissue specimens was strikingly lower than that in the control group (P<0.001). Based on the median value of PLK2 mRNA expression in GBM tissues, 50 GBM patients were categorized into the high-expression group (n=20) and the low-expression group (n=30). Multivariate Cox regression analysis demonstrated that high expression of PLK2 mRNA was an independent risk factor for the unfavorable survival prognosis of GBM patients (P<0.05). The Kaplan-Meier curve revealed that the median OS of GBM patients with low expression of PLK2 mRNA was longer (15.5 months vs. 10.0 months; P<0.001). The expression level of PLK2 mRNA in GBM tissues with hypermethylation of PLK2 was even lower (P<0.001). Conclusions PLK2 is expressed at a relatively low level in GBM tissues, which might be regulated by the methylation of its DNA promoter. The lower expression of PLK2 in GBM tissues could potentially serve as an independent prognostic factor for GBM patients.

参考文献/References:

[1]ZHAO YM, XU HY. Bioinformatics analysis on related genes and candidate pathways of glioblastoma multiforme [J]. J Jilin University (Medicine Edition), 2023, 49(5): 1280-1289. 赵一明，许海洋. 多形性胶质母细胞瘤相关基因和候选通路的生物信息学分析[J]. 吉林大学学报（医学版），2023，49（5）：1280-1289.
[2]PEARSON JRD, CUZZUBBO S, MCARTHUR S, et al. Immuneescape in glioblastoma multiforme and the adaptation of immunotherapies for treatment [J]. Front Immunol, 2020, 11: 582106-582131.
[3]KANT TA, NEWE M, WINTER L, et al. Genetic deletion of pololike kinase 2 induces a pro-fibrotic pulmonary phenotype [J]. Cells, 2021, 10(3): 617-631.
[4]WANG JW, BAO XJ, SUN T, et al. Comprehensive analysis of PLKs expression and prognosis in breast cancer [J]. Cancer Genet, 2022, 268-269: 83-92.
[5]KIM DE, BYEON HE, KIM DH, et al. Plk2-mediated phosphorylation and translocalization of Nrf2 activates anti-inflammation through p53/Plk2/p21cip1 signaling in acute kidney injury [J]. Cell Biol Toxicol, 2023, 39(4): 1509-1529.
[6]ROCKWELL NC, YANG W, WARRINGTON NM, et al. Sex- and mutation-specific p53 gain-of-function activity in gliomagenesis [J]. Cancer Res Commun, 2021, 1(3): 148-163.
[7]TANG Y, QING C, WANG J, et al. DNA methylation-based diagnostic and prognostic biomarkers for glioblastoma [J]. Cell Transplant, 2020, 29: 963689720933241-963689720933254.
[8]DENG S, LU X, ZHANG Z, et al. Identification and assessment of PLK1/2/3/4 in lung adenocarcinoma and lung squamous cell carcinoma: evidence from methylation profile [J]. J Cell Mol Med, 2021, 25(14): 6652-6663.
[9]DAS S, DASH BS, PREMJI TP, et al. Immunotherapeutic approaches for the treatment of glioblastoma multiforme: mechanism and clinical applications [J]. Int J Mol Sci, 2023, 24(13): 10546-10571.
[10]BISEROVA K, JAKOVLEVS A, ULJANOVS R, et al. Cancer stem cells: significance in origin, pathogenesis and treatment of glioblastoma [J]. Cells, 2021, 10(3): 621-640.
[11]LUO L, ZHANG XY, ZHEN YW, et al. Polo-like kinase 1 is related with malignant characteristics and inhibits macrophages infiltration in glioma [J]. Front Immunol, 2022, 13: 1058036-1058057.
[12]WANG J, ZUO J, WANG M, et al. Polo-like kinase 4 promotes tumorigenesis and induces resistance to radiotherapy in glioblastoma [J]. Oncol Rep, 2019, 41(4): 2159-2167.
[13]WEN J, WANG Q, ZHANG W, et al. TUBA1A licenses APC/C mediated mitotic progression to drive glioblastoma growth by inhibiting PLK3 [J]. FEBS letters, 2023, 597(24): 3072-3086.
[14]MATTHEW EM, YANG Z, PERI S, et al. Plk2 loss commonly occurs in colorectal carcinomas but not adenomas: relationship to mTOR signaling [J]. Neoplasia, 2018, 20(3): 244-255.
[15]CAO F, XIA X, FAN Y, et al. Knocking down of Polo-like kinase 2 inhibits cell proliferation and induced cell apoptosis in human glioma cells [J]. Life Sci, 2021, 270: 119084-119092.
[16]TAN S, ZHAO J, WANG P. DYRK1A-mediated PLK2 phosphorylation regulates the proliferation and invasion of glioblastoma cells [J]. Int J Oncol, 2023, 63(2): 94-107.
[17]KARLOW JA, MIAO B, XING X, et al. Common DNA methylation dynamics in endometriod adenocarcinoma and glioblastoma suggest universal epigenomic alterations in tumorigenesis [J]. Commun Biol, 2021, 4(1): 607-623.
[18]XIA X, CAO F, YUAN X, et al. Low expression or hypermethylation of PLK2 might predict favorable prognosis for patients with glioblastoma multiforme [J]. PeerJ, 2019, 7: e7974-e7992.

相似文献/References:

[1]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(05):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述　高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强　杨吉安　邵灵敏　吴庭枫　刘宝辉　陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
　LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(05):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇　冯　军　黄俊红　白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
　GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(05):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕　孟凡华　刘魏然　魏春晓　林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
　WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(05):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元　王汉东　樊友武　贾　玥　吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
　ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(05):69.
[7]郑锐哲　姜秀峰　陈二涛　孙兆良　冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
　HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(05):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安　陆　南　贺亚龙　章　翔　刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
　YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(05):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴　蛟　易　勇　赵卓琳　周良学　周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
　WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(05):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]

备注/Memo

备注/Memo:
（2023-12-12收稿，2024-01-05修回）
基金项目：河南省医学科技攻关计划项目（LHGJ202008）
更新日期/Last Update: 2024-05-30